Work

Tolerability and adverse events experienced by women with ovarian cancer treated with intravenous or intraperitoneal chemotherapy plus veliparib and bevacizumab based on BRCA status

Year: 2020

Type: article

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2020.06.029

Authors: J. Gillen, A. Miller, K.N. Moore, K.M. Bell-McGuinn, R. Schilder, J.L. Walker, W.E. Brady, R.E. O'Cearbhaill, S.R. Guntupalli, D.K. Armstrong, A.R. Hagemann, H.J. Gray, L.R. Duska, C.A. Mathews, A. Chen, D.M. O'Malley, S.W. Gordon, P.M. Fracasso, C. Aghajanian

Institutions: University of Oklahoma Health Sciences Center, Roswell Park Comprehensive Cancer Center, OU Health Stephenson Cancer Center, Memorial Sloan Kettering Cancer Center, Thomas Jefferson University, University of Oklahoma, University of Colorado Denver, Sidney Kimmel Comprehensive Cancer Center, Washington University in St. Louis, University of Washington Medical Center, University of Virginia, Brown University, National Institutes of Health, National Cancer Institute, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Virginia Commonwealth University

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3016973640

FWCI:

Cites:

Cited by:

Related to: 10